Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Immunotherapy (Tebentafusp) and Radiation Therapy (Yttrium-90 Radioembolization) for the Treatment of Uveal Melanoma Metastatic to the Liver

Trial Status: active

This phase II trial studies the safety and side effects of tebentafusp in combination with yttrium-90 (Y-90) radioembolization, and how well they work in treating patients with uveal melanoma that has spread from where it first started to the liver (metastatic). Tebentafusp works by attracting specific types of cells called T-cells to abnormal cells. T-cells are part of the body’s immune system, which help fight infections and can also find and kill abnormal cells. However, abnormal cells that have become cancerous find ways to shut down the immune system’s defenses. Tebentafusp may help T-cells find and attack uveal melanoma cells. Y-90 radioembolization is a type of radiation therapy used for patients with tumors in the liver. During this procedure, microscopic glass beads containing yttrium-90, a radioactive element, are inserted into liver tumors using a thin, flexible tube called a catheter. The radioactivity emitted from the glass beads directly injures and kills uveal melanoma tumor cells in the liver and may also activate the body’s immune systems to find and attack other uveal melanoma cells in the body. Tebentafusp in combination with Y-90 radioembolization may be safe and effective in treating uveal melanoma metastatic to the liver.